Equine Anaplasmosis Study Guide

Overview and Clinical Importance

Equine Granulocytic Anaplasmosis (EGA) is a tick-borne infectious disease caused by the obligate intracellular bacterium Anaplasma phagocytophilum. This rickettsial organism infects granulocytes, primarily neutrophils, leading to a characteristic febrile illness. EGA is a seasonal, noncontagious disease transmitted by Ixodes species ticks and represents an important differential diagnosis for horses presenting with fever and hematologic abnormalities.

The disease was previously known as Equine Granulocytic Ehrlichiosis when the causative agent was classified as Ehrlichia equi. Taxonomic reclassification in 2001 unified this organism with the human granulocytic ehrlichiosis agent into a single species, A. phagocytophilum. This is clinically significant because equine and canine infections serve as sentinel indicators for human risk in endemic areas.

Etiology and Pathogenesis

Causative Agent

Anaplasma phagocytophilum is an obligate intracellular, Gram-negative, pleomorphic coccoid bacterium belonging to the order Rickettsiales and family Anaplasmataceae. The organism specifically targets granulocytes, particularly neutrophils and occasionally eosinophils, where it replicates within membrane-bound cytoplasmic vacuoles.

Organism Characteristics

Pathogenesis

Following tick transmission, A. phagocytophilum binds to PSGL-1 (P-selectin glycoprotein ligand-1) on neutrophil surfaces via the 44-kDa major surface protein-2 (Msp2). The organism enters the cell and prevents phagolysosome fusion, allowing it to survive and replicate within the endosomal compartment. This process disrupts normal neutrophil functions including:

• Phagocytosis and respiratory burst capability
• Endothelial cell adhesion and transmigration
• Degranulation and antimicrobial peptide release
• Normal apoptotic pathways (delayed apoptosis prolongs bacterial survival)

The resulting vasculitis is the primary pathologic lesion, particularly affecting the distal limbs. This explains the characteristic distal limb edema seen clinically. The organism also increases IL-8 secretion, which paradoxically enhances neutrophil recruitment and subsequent infection of additional cells.

Epidemiology and Transmission

Geographic Distribution

EGA is distributed worldwide, with documented cases in North America, Europe, Asia, Africa, and South America. In the United States, the disease correlates with the distribution of Ixodes tick species:

• Eastern United States: Ixodes scapularis (blacklegged or deer tick)
• Western United States: Ixodes pacificus (western blacklegged tick)
• Europe: Ixodes ricinus (castor bean tick)
• Asia: Ixodes persulcatus (taiga tick)

Seasonality

EGA demonstrates marked seasonal occurrence correlating with tick activity. Peak incidence occurs during:

• Late fall through early spring - Primary season (corresponds to adult tick activity)
• Late spring through early summer - Secondary peak (nymphal tick activity)

Exam Focus: The seasonality of EGA (late fall to spring) helps differentiate it from Potomac Horse Fever (PHF), which occurs primarily in late summer to early fall (July-September). This is a common board question!

Transmission and Risk Factors

Clinical Presentation

Classic Clinical Signs

Clinical signs typically appear 1-3 weeks post-infection and vary in severity based on age, immune status, and previous exposure. A systematic review of 189 clinical cases found the following frequencies of clinical signs:

Disease Progression

Phase 1 (Days 1-3): Acute febrile phase with high fever (103-106°F), lethargy, and reduced appetite

Phase 2 (Days 3-5): More severe signs develop including icterus, distal limb edema, petechiation, and reluctance to move

Recovery Phase: Most horses recover over 2-3 weeks even without treatment; treated horses improve within 24-36 hours

Atypical Presentations

While most cases present with classic signs, several atypical presentations have been documented:

• Neurologic Disease (41% in one study): Symmetrical diffuse proprioceptive ataxia most common
• Myopathy/Rhabdomyolysis: Severe muscle pain, markedly elevated CK and AST; Quarter Horses with MYHM gene may be predisposed
• Peritoneal Effusion: Uncommon but reported
• Cardiomyopathy: Rare complication
• DIC (Disseminated Intravascular Coagulation): Rare, severe complication

Diagnosis

Hematologic Abnormalities

Laboratory findings reflect the organism's tropism for granulocytes and the resulting vasculitis:

Definitive Diagnostic Methods

Differential Diagnosis

The differential diagnosis for a febrile horse with hematologic abnormalities includes several important conditions:

EGA (Anaplasmosis): Fall/Winter/Spring, NO diarrhea, NO laminitis, distal limb edema

PHF: Summer/Early Fall, diarrhea common, LAMINITIS (15-25%), colitis signs

Treatment

Antimicrobial Therapy

A. phagocytophilum is highly susceptible to tetracycline-class antimicrobials. Rapid clinical improvement (24-36 hours) is expected with appropriate treatment.

Important Treatment Considerations

• Oxytetracycline administration: Dilute in saline (NOT lactated Ringer's solution) and administer slowly IV to prevent hypotension, collapse, and renal tubular necrosis
• Collect diagnostics BEFORE treatment: Obtain blood for PCR and blood smear before initiating antimicrobials
• Short treatment courses may lead to relapse: Complete the full 5-7 day course
• Ineffective antibiotics: Penicillin, chloramphenicol, and streptomycin have NO activity against A. phagocytophilum

Supportive Care

• NSAIDs: Flunixin meglumine (1.1 mg/kg IV) for fever, pain, and inflammation
• Fluid therapy: Intravenous fluids if dehydrated or severely affected
• Corticosteroids: Dexamethasone (0.1 mg/kg IV/PO/IM q24h for 2-3 days) may benefit horses with severe limb edema or neurologic signs
• Leg wraps: Standing wraps may help reduce distal limb edema

Prognosis and Prevention

Prognosis

The prognosis for EGA is excellent with appropriate treatment:

• Mortality is rare with treatment
• Most horses recover within 2-3 weeks even without treatment
• Treated horses show clinical improvement within 24-36 hours
• Long-term sequelae are not typically reported
• Recovered horses develop immunity lasting at least 2 years
• Chronic carrier state has not been definitively established

Prevention

No vaccine is available for equine anaplasmosis. Prevention focuses on tick control:

• Daily tick inspection: Examine horses daily during tick season and remove attached ticks promptly
• Tick repellents: Permethrin-based products, cypermethrin, pyrethrins with variable efficacy
• Environmental management ("Tickscaping"): Remove leaf litter and woody debris, mow pastures, maintain dry well-lit paddocks
• Needle hygiene: Never share needles between horses to prevent iatrogenic transmission